Taenaka, Hiroki
Wick, Katherine D.
Sarma, Aartik
Matsumoto, Shotaro
Ghale, Rajani
Fang, Xiaohui
Maishan, Mazharul
Gotts, Jeffrey E.
Langelier, Charles R.
Calfee, Carolyn S.
Matthay, Michael A.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (5T32GM008440-24, K23HL163491, HL140026, HL123004)
Article History
Received: 17 February 2024
Accepted: 17 May 2024
First Online: 29 May 2024
Declarations
:
: The study protocol was approved by the University of California San Francisco (UCSF) Institutional Review Board (17-24056). If a patient was able to consent or had a surrogate available, a study physician or research coordinator obtained written informed consent at the time of enrollment. For subjects who could not consent at enrollment, the UCSF IRB granted an initial waiver of informed consent for biospecimen and clinical data collection, as previously described []. The UCSF IRB also approved a full waiver of consent for patients who died prior to regaining an ability provide informed consent, but restricted data sharing for samples collected from these patients. Because some of the subjects included in the present study were enrolled under a waiver of consent, our IRB protocol prohibits the public release of raw sequencing data, which may contain personally identifiable genetic information. The animal experiments were approved by the UCSF Institutional Animal Care and Use Committee (AN189182), were performed in compliance with the National Institute of Health Guide for Care and Use of Laboratory Animals and were reported in accordance with the Animal Research: Report of In Vivo Experiments (ARRIVE) guidelines.
: Not applicable.
: The authors declare that they have no competing interests.